• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Role of Long-Acting Bronchodilators in Patients with Clinical Asthma Remission.

作者信息

Milger Katrin

机构信息

Department of Medicine V, LMU University Hospital Munich, Munich, Germany.

出版信息

Respiration. 2024;103(10):630-633. doi: 10.1159/000540298. Epub 2024 Aug 6.

DOI:10.1159/000540298
PMID:39106840
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11446295/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9b4/11446295/47c6e0e55bfb/res-2024-0103-0010-540298_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9b4/11446295/47c6e0e55bfb/res-2024-0103-0010-540298_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9b4/11446295/47c6e0e55bfb/res-2024-0103-0010-540298_F01.jpg

相似文献

1
Role of Long-Acting Bronchodilators in Patients with Clinical Asthma Remission.长效支气管扩张剂在临床哮喘缓解患者中的作用
Respiration. 2024;103(10):630-633. doi: 10.1159/000540298. Epub 2024 Aug 6.
2
[Long-acting beta2-agonist bronchodilators safety for asthma treatment].长效β2受体激动剂支气管扩张剂用于哮喘治疗的安全性
Arch Argent Pediatr. 2009 Aug;107(4):291-3. doi: 10.1590/S0325-00752009000400002.
3
Long-acting inhaled bronchodilators for cystic fibrosis.用于囊性纤维化的长效吸入型支气管扩张剂。
Cochrane Database Syst Rev. 2017 Dec 19;12(12):CD012102. doi: 10.1002/14651858.CD012102.pub2.
4
Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?长效抗胆碱能支气管扩张剂在哮喘中有作用机制和作用吗？
NPJ Prim Care Respir Med. 2014 Jul 17;24:14023. doi: 10.1038/npjpcrm.2014.23.
5
Tiotropium – what role in asthma?噻托溴铵——在哮喘中起什么作用？
Drug Ther Bull. 2015 Sep;53(9):102-4. doi: 10.1136/dtb.2015.9.0349.
6
Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long-acting beta-agonists with inhaled corticosteroids.最佳哮喘治疗的双重成分：联合使用长效β受体激动剂与吸入性糖皮质激素的科学及临床依据
J Am Osteopath Assoc. 2001 Sep;101(9):526-33.
7
Pharmacology and therapeutics of bronchodilators.支气管扩张剂的药理学和治疗学。
Pharmacol Rev. 2012 Jul;64(3):450-504. doi: 10.1124/pr.111.004580. Epub 2012 May 18.
8
Pharmacology and Therapeutics of Bronchodilators Revisited.重新审视支气管扩张剂的药理学和治疗学
Pharmacol Rev. 2020 Jan;72(1):218-252. doi: 10.1124/pr.119.018150.
9
The reality of LAMAs for adult asthmatic patients.长效抗胆碱能药物在成年哮喘患者中的现实情况。
Expert Rev Respir Med. 2020 Nov;14(11):1087-1094. doi: 10.1080/17476348.2020.1794828. Epub 2020 Jul 20.
10
Novel bronchodilators in asthma.哮喘的新型支气管扩张剂。
Curr Opin Pulm Med. 2010 Jan;16(1):6-12. doi: 10.1097/MCP.0b013e32833303d2.

本文引用的文献

1
Pioneering a paradigm shift in asthma management: remission as a treatment goal.开创哮喘管理的范式转变：将缓解作为治疗目标。
Lancet Respir Med. 2024 Feb;12(2):96-99. doi: 10.1016/S2213-2600(23)00415-0. Epub 2023 Dec 7.
2
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.贝那鲁肽治疗重度嗜酸性粒细胞性哮喘患者的每日维持吸入性皮质类固醇的降低（SHAMAL）：一项随机、多中心、开放性、4 期研究。
Lancet. 2024 Jan 20;403(10423):271-281. doi: 10.1016/S0140-6736(23)02284-5. Epub 2023 Dec 7.
3
Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort.
成人德国哮喘网络严重哮喘登记处队列中生物制剂治疗的反应和临床缓解。
J Allergy Clin Immunol Pract. 2023 Sep;11(9):2701-2712.e2. doi: 10.1016/j.jaip.2023.05.047. Epub 2023 Jun 8.
4
Improvements in asthma control and quality of life with benralizumab are unrelated to baseline bronchodilator response.
J Allergy Clin Immunol Pract. 2022 Dec;10(12):3342. doi: 10.1016/j.jaip.2022.07.040.
5
Overall Response to Anti-IL-5/Anti-IL5-Rα Treatment in Severe Asthma Does Not Depend on Initial Bronchodilator Responsiveness.重度哮喘患者对抗白细胞介素-5/抗白细胞介素-5受体α治疗的总体反应并不取决于初始支气管扩张剂反应性。
J Allergy Clin Immunol Pract. 2022 Dec;10(12):3174-3183. doi: 10.1016/j.jaip.2022.07.007. Epub 2022 Jul 21.
6
Disease-modifying anti-asthmatic drugs.疾病修饰抗哮喘药物。
Lancet. 2022 Apr 23;399(10335):1664-1668. doi: 10.1016/S0140-6736(22)00331-2.
7
Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and Meta-analysis.三联吸入器疗法与中重度哮喘的哮喘结局：系统评价和荟萃分析。
JAMA. 2021 Jun 22;325(24):2466-2479. doi: 10.1001/jama.2021.7872.
8
Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review.哮喘患者吸入皮质类固醇的全身不良反应：系统评价。
BMJ Open Respir Res. 2020 Dec;7(1). doi: 10.1136/bmjresp-2020-000756.
9
Health Services Utilization Is Increased in Poor Perceivers of Bronchoconstriction and Hyperinflation in Asthma.哮喘患者中支气管收缩和肺过度充气感知较差者的医疗服务利用率增加。
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2643-2650.e2. doi: 10.1016/j.jaip.2020.03.045. Epub 2020 Apr 15.
10
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.贝那利珠单抗，一种抗白细胞介素-5 受体 α 的单克隆抗体，作为附加治疗用于严重、未控制、嗜酸性粒细胞性哮喘（CALIMA）患者：一项随机、双盲、安慰剂对照的 3 期试验。
Lancet. 2016 Oct 29;388(10056):2128-2141. doi: 10.1016/S0140-6736(16)31322-8. Epub 2016 Sep 5.